Association between NSAID and Statin Therapy and the Incidence of Intravitreal Anti-vascular Endothelial Growth Factor Injections and Nd:YAG Laser Treatment after Cataract Surgery in Finland


Purpose: To examine the association between the use of topical non-steroidal antiinflammatory (NSAID) medication, systemic statin therapy, and the incidence rate of two of the most common postsurgical procedures in adult patients undergoing cataract surgery in Finland between January 1, 2010 and December 31, 2016.

Methods: This retrospective, nationwide cohort study considered 176,052 cataract operations coded with the International Classification of Disease coding: early adult (H25.0), normal (H25.1), other senile (H25.8), pre-senile (H26.02), or other (related to trauma, other eye disease, or medication). Operations were linked to purchased and reimbursed medications using Anatomical Therapeutic Chemical codes. The incidence rate of intravitreal anti-vascular endothelial growth factor (VEGF) injections, and neodymium-doped yttrium aluminum (Nd:YAG) laser treatments of posterior capsular opacification were evaluated using the Poisson regression model.

Results: In our registry cohort, patients with a prescription of topical NSAID (ketorolac) at the time of cataract surgery were less likely treated with intravitreal anti-VEGF injections after surgery (adjusted Poisson regression model IRR 0.3; 95% CI: 0.15–0.60, P = 0.0007), and also had reduced incidence of Nd:YAG laser (0.59, CI: 0.43–0.81, P = 0.0011) treatments. Unlike topical NSAID, the use of systemic statin therapy was not associated with these two most common surgical procedures (RR 1.04, 95% CI: 0.96–1.12, P = 0.33).

Conclusion: The use of topical NSAIDs is associated with reduced rates of intravitreal anti-VEGF injections and Nd:YAG laser treatments after cataract surgery. More observational and experimental studies are warranted to confirm possible benefits of topical NSAID administration after cataract surgery.


Anti-inflammatory, Capsulotomy, Cataract Surgery, Cystic Macular Edema, Epidemiology, Intravitreal Injection, Ketorolac, Nationwide Cohort Study, NSAID, Secondary Cataract, Statin Therapy

1. Eurostat. Surgical operations and procedures statistics – statistics explained [Internet]. Eurostat; 2020 [cited 2017 Nov 30]. Available from: http://ec. Surgical_operations_and_procedures_statistics&oldid= 27060.

2. Ursell PG, Dhariwal M, Majirska K, Ender F, Kalson-Ray S, Venerus A, et al. Three-year incidence of Nd:YAG capsulotomy and posterior capsule opacification and its relationship to monofocal acrylic IOL biomaterial: a UK Real World Evidence study. Eye 2018;32:1579–1589.

3. Kessel L, Tendal B, Jørgensen KJ, Erngaard D, Flesner P, Lundgaard Andresen J, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology 2014;121:1915–1924.

4. Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging 2016;11:1221–1229.

5. Park JH, Yoo C, Kim YY. E?ect of lovastatin on woundhealing modulation after glaucoma filtration surgery in a rabbit model. Invest Ophthalmol Vis Sci 2016:57:1871– 1877.

6. Loukovaara S, Sahanne S, Takala A, Haukka J. Statin use and vitreoretinal surgery: findings from a Finnish population-based cohort study. Acta Ophthalmol 2018:96:442–451.

7. Ooi KG, Khoo P, Vaclavik V, Watson SL. Statins in ophthalmology. Surv Ophthalmol 2019:64:401–432.

8. Kawahara S, Hata Y, Kita T, Arita R, Miura M, Nakao S, et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 2008;57:2784– 2793.

9. Tuuminen R, Sahanne S, Loukovaara S. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment. Acta Ophthalmol 2014;92:675–681.

10. Tuuminen R, Haukka J, Loukovaara S. Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients. Graefe’s Arch Clin Exp Ophthalmol 2015;253:1685–1693

11. Vail D, Callaway NF, Ludwig CA, Saroj N, Moshfeghi DM. Lipid-lowering medications are associated with lower risk of retinopathy and ophthalmic interventions among U.S. patients with diabetes. Am J Ophthalmol 2019;207:378– 384.

12. Kang E Y, Chen TH, Garg SJ, Sun C-C, Kang J-H, Wu WC, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol 2019:137:363–371.

13. Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L. Statin use and the risk of cataracts: a systematic review and meta-analysis. J Am Heart Assoc 2017;6:e004180.

14. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2019. Available from:

15. Stein JD, Grossman DS, Mundy KM, Sugar A, Sloan FA. Severe adverse events after cataract surgery among Medicare beneficiaries. Ophthalmology 2011;118:1716– 1723.

16. Stein JD. Serious adverse events after cataract surgery. Curr Opin Ophthalmol 2012;23:219–225.

17. Duan P, Liu Y, Li J. The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol 2017;255:639–649.

18. Anisimova NS, Arbisser LB, Petrovski G, Petrichuk SV, Sobolev NP, Petrovski B, et al. Effect of NSAIDs on pupil diameter and expression of aqueous humor cytokines in FLACS versus conventional phacoemulsification. J Refract Surg 2018;34:646–652.

19. Loukovaara S, Lehtinen V, Nieminen R, Moilanen J. Topical levofloxacin, nepafenac and prednisolone acetate medication after cataract surgery in the biggest tertiary eye hospital in Finland during 2015-2018. Acta Ophthalmol 2019;97:e943–e945.

20. Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc 1976;74:637–660.

21. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977;203:81–88.

22. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25:699–704.

23. Coassin M, Iovieno A, Soldani A, Cavuto S, Cimino L, Sartori A, et al. Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndrome. J Cataract Refract Surg 2016;42:1119–1125.

24. Relhan N, Forster RK, Flynn HW Jr. Endophthalmitis: then and now. Am J Ophthalmol 2018;187:xx–xxvii.

25. Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res 2017;60:44–65.

26. Tuuminen R, Loukovaara S. Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels. Clin Ophthalmol 2016;23:921–928.

27. Al-Janabi A, Lightman S, Tomkins-Netzer O. Statins in retinal disease. Eye 2018;32:981–991.

28. Lee CM, Afshari NA. The global state of cataract blindness. Curr Opin Ophthalmol 2018;28:98–103.

29. Salowi MA, Goh PP, Lee MY, Adnan TH, Ismail M. The Malaysian Cataract Surgery Registry: profile of patients presenting for cataract surgery. Asia Pac J Ophthalmol 2015;4:191–196.

30. Wang W, Yan W, Fotis K, Prasad NM, Lansingh VC, Taylor HR, et al. Cataract surgical rate and socioeconomics: a global study. Invest Ophthalmol Vis Sci 2016;57:5872– 5881.